ArticleBMC gastroenterology2026
Eradication efficacy of empiric bismuth quadruple therapy containing amoxicillin in the first-line treatment of Helicobacter pylori in Ningxia, China.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the eradication rate and safety of bismuth quadruple therapy containing amoxicillin as a first-line empiric treatment in patients with high resistance to Helicobacter pylori (H. pylori) in China.
methodsThis retrospective study included 874 patients with H. pylori infection who attended the outpatient clinic of the Department of Gastroenterology of the People’s Hospital of Ningxia Hui Autonomous Region from June 2021 to October 2022 and met the criteria for exclusion, including the Esomeprazole-Bismuth-Amoxicillin-Clarithromycin (EBAC) group, the Esomeprazole-Bismuth-Amoxicillin-Levofloxacin (EBAL) group, the Esomeprazole-Bismuth-Amoxicillin-Furazolidone (EBAF) group, the Esomeprazole-Bismuth-Amoxicillin-Tetracycline (EBAT) group, and the duration of treatment was 14 days. Eradication of H. pylori was determined using a repeat 14-carbon urease breath test (14 C-UBT) at weeks 4–6 after the end of treatment.
resultsIn the intention-to-treat analysis (ITT), the eradication rates of H. pylori in the EBAC, EBAL, EBAF, and EBAT groups were 73.2% (198.5/271), 69.0% ( 184.9/268), 71.8% (109.2/152), and 71.5% (130.2/183), respectively; and in the per-protocol (PP) analysis, the PP analysis eradication rates were 83.2% (203.9/245), 81.2% (193.3/238), 90.0% (124.3/138), and 82.5% (136.1/165), and the differences in the eradication rates of the four groups for ITT and PP analysis were not statistically significant (ITT: P = 0.845; PP: P = 0.470). The incidence rates of adverse event(AE) in the EBAC, EBAL, EBAF, and EBAT groups were 15.0% (40.6/271), 8.0% (21.3/268), 23.2% (35.3/152), and 24.8% (45.1/183), respectively, with statistically significant differences (P < 0.001).
conclusionThe eradication rates of four amoxicillin-containing bismuth quadruple therapy regimens in Ningxia were not significantly different. However, the EBAF regimen showed favorable trends in terms of increased eradication rate, better cost-effectiveness, and controllable adverse events, its efficacy and tolerability should be weighed, and the monitoring of drug use should be strengthened.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.